Kraig Biocraft Laboratories' COO Jon Rice will present at the International Sericultural Commission Congress in Chennai, India, on the commercial impact of genetically engineered recombinant spider silk. The presentation highlights how this breakthrough technology integrates with existing silk industry infrastructure, promising to reshape the $18 billion silk market with new applications and economic opportunities. This event offers Kraig Labs a platform to expand industry relationships and explore new commercialization avenues in a key silk-producing region.
Kraig Biocraft Laboratories' presentation on bioengineered silk comes with this Pluang Basic Materials sector snapshot as of Oct 19, 2026 18:11 WIB: Of 83 priced US stocks, 44 rose and 29 fell today. Notable movers include Sasol Ltd. American Depositary Shares (SSL) at USD 16.00 with a -2.08% change and a typical hold time of 3 days, MP Materials (MP) at USD 40.77 with a +1.49% change and a typical hold time of 16 days, and Albemarle Corp. (ALB) at USD 96.90 with a +1.49% change and a typical hold time of 51 days. The most notable figure is Albemarle Corp.'s price of USD 96.90.
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...
EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...
